If a non-substitutable Lovenox knockoff entered the market, MNTA would continue to get a 45% share of NVS’ Lovenox profits, i.e. the same economics as the current arrangement.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”